Articles from Cognition Therapeutics, Inc.

– Study demonstrated strong therapeutic responses across behavioral, functional, cognitive, and movement measures in patients with mild-to-moderate DLB –

PURCHASE, N.Y., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQCGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that CEO Lisa Ricciardi will be participating at upcoming conferences taking place during the week of the JP Morgan Healthcare Conference 2025.

- Improvements Across Measures of Behavior, Function, Cognition and Movement -

– Topline results in second dementia indication expected to be reported in December 2024 –

- Dramatic 95% Reduction of Cognitive Decline in CT1812-treated Patients with Lower Plasma p-tau217 Correlated with Improvements in Key Indicators of Alzheimer’s Disease Biology -

- CT1812 slowed cognitive decline by 95% in Alzheimer’s disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from Phase 2 SHINE study presented at CTAD -

PURCHASE, N.Y., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQCGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that President and CEO Lisa Ricciardi will present live at the virtual Zacks SCR Life Sciences Investor Forum on November 14, 2024. The Company’s presentation will focus primarily on the results from the successful Phase 2 ‘SHINE’ study of CT1812 in mild-to-moderate Alzheimer’s disease. In addition, Ms. Ricciardi will provide an overview of the Company’s ongoing clinical programs, including the Phase 2 ‘SHIMMER’ study of CT1812 in dementia with Lewy bodies. Topline results from the ‘SHIMMER’ study are expected by year-end 2024.

- Patient characteristics are consistent with other DLB studies -

- Results show CT1812 dramatically slowed cognitive decline in patients with lower levels of plasma p-tau217, an important biomarker of Alzheimer’s disease pathology - 

Presenting prespecified analysis of cognitive impact on plasma p-Tau 217 subgroups in ‘SHINE’

PURCHASE, N.Y., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQCGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, has released a new Conversations video podcast episode. The new episode, which has been launched during DLB Awareness Month, is titled “Executing Clinical Research in Dementia with Lewy Bodies (DLB).”

PURCHASE, N.Y., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQCGTX), a clinical-stage company developing drugs to treat neurodegenerative disorders, today announced the Company’s president and CEO Lisa Ricciardi will participate in a panel discussion titled Frontiers in Neuroscience during the 3rd Annual Roth Healthcare Opportunities Conference on October 9, 2024.

Cognition is advancing CT1812 in the Phase 2 ‘SHIMMER’ clinical trial for the treatment of dementia with Lewy bodies with data readout in the fourth quarter of 2024

PURCHASE, N.Y., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQCGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today announced the Company’s president and CEO, Lisa Ricciardi will participate in two investor conferences in September.

PURCHASE, N.Y., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQCGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that results from the SEQUEL study of CT1812, the Company’s lead candidate for the treatment of Alzheimer’s disease, were published in The Journal of Prevention of Alzheimer's Disease. SEQUEL was a single-site study that measured brain wave patterns in 16 adults with mild-to-moderate Alzheimer’s disease following 29-days of treatment with CT1812 or placebo. In this study, CT1812-treated participants exhibited consistent trends of improvement across all prespecified electroencephalography (EEG) parameters with several reaching significance, including the change in relative theta power in the central region (p=0.006) of the brain and AEC-c* (p=0.034), which assesses the connectivity between brain regions.

- Proof-of-Concept Phase 2 SHINE Trial Demonstrates ~40% Mean Improvement in ADAS-Cog 11 vs Placebo and Consistent Positive Changes Across Multiple Cognitive and Functional Measures -

- Conference Call and Live Audio Webcast Scheduled for August 8, 2024 -

- CT1812 Treatment Showed ~40% Mean Improvement in Cognitive Measures vs Placebo -- Consistent Positive Changes Across Cognitive and Functional Measures -- Favorable Safety Profile with Most Treatment-Related Adverse Events Mild or Moderate -- Significant Changes in Neurofilament Light Chain, a Marker of Neurodegeneration -- Investor Webcast to be Conducted at 8:30a.m. ET to Review Findings -

PURCHASE, N.Y., July 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQCGTX), a clinical stage company developing drugs that treat neurodegenerative disorders will host an investor webcast on Monday, July 29, 2024 at 8:30a.m. ET to discuss the clinical efficacy, safety and biomarker findings from the Phase 2 COG0201 “SHINE” study. SHINE enrolled 153 adults with mild-to-moderate Alzheimer’s disease who were randomized to receive once-daily oral doses of CT1812 (100mg or 300mg) or placebo for six months. The only way to participate in the live webcast is to register online by clicking here. The event will also be archived on the Investor Relations section of the Cognition website.

PURCHASE, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQCGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that abstracts summarizing clinical efficacy, safety and biomarker findings from the Phase 2 COG0201 “SHINE” study of CT1812 have been accepted for poster presentation at the upcoming Alzheimer’s Association’s International Conference being held in Philadelphia, PA from July 28-August 1, 2024.

PURCHASE, N.Y., May 21, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQCGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, has released its eighth Conversations video podcast episode: “Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease.” This episode reviews how beta amyloid (Aβ) oligomers cause synaptic dysfunction, which is correlated with cognitive decline.

- Topline Results from SHINE Study in Mild-to-Moderate Alzheimer’s Expected Mid-2024 -- SHIMMER Study in Dementia with Lewy Bodies Completed Enrollment of 130 Participants -

- Top-line Results Expected in the Second Half of 2024 -

PURCHASE, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQCGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, provided a recap of the virtual KOL event hosted on April 12, 2024 featuring Martin J. Sadowski, MD, PhD, DSci of the NYU School of Medicine; Anton Porsteinsson, MD of the University of Rochester Alzheimer's Disease Care, Research and Education Program; and Everard (Jort) Vijverberg, MD, PhD of the Alzheimer Center Amsterdam and Neuroscience Amsterdam.

PURCHASE, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQCGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced today that the Company’s president and CEO, Lisa Ricciardi, will present at the 23rd Annual Needham Virtual Healthcare Conference taking place April 8-11, 2024. During her presentation, Ms. Ricciardi will review recent corporate accomplishments and anticipated clinical milestones.

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQCGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced it will host a virtual KOL event on Friday, April 12, 2024 from 8:00 AM to 9:30 AM ET. The live and archived event may be accessed from the investor relations section of the Cognition website. To register, please click here.

- Topline Results from SHINE Study in Mild-to-Moderate Alzheimer’s Expected mid-2024 -- On Track to Report Topline Results from SHIMMER Study in Mild-to-Moderate DLB in 2H 2024 - - 1Q 2024 Capital Raise Extends Cash Runway Through May 2025 -- Webcast Conference Call Scheduled Today at 8:00 a.m. ET -

Conference Call and Live Audio Webcast Scheduled for March 26, 2024

PURCHASE, N.Y., March 14, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (“Cognition,” the “Company” or “We”) (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced today the closing of its previously announced underwritten public offering of 6,571,428 shares of its common stock. Each share of common stock was sold at a price to the public of $1.75 per share. The gross proceeds to the Company from the offering were approximately $11.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from this offering to fund research, clinical development, process development and manufacturing of Cognition’s product candidates, working capital, capital expenditures and other general corporate purposes.

PURCHASE, N. Y., March 11, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (“Cognition,” the “Company” or “We”) (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, today announced that it has commenced an underwritten public offering (the “offering”) of shares of its common stock. Cognition also intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the aggregate number of shares of its common stock to be sold in the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the shares of common stock to be sold in the proposed offering will be sold by Cognition.

PITTSBURGH, March 06, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQCGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), is presenting results of proteomic and correlation analyses of two completed clinical studies at the AD/PD™ 2024 Alzheimer's & Parkinson's Diseases Conference (March 5-9, 2024 in Lisbon, Portugal). The three posters, which are listed below, summarize proteomic analyses from the completed SEQUEL and SPARC studies, which were conducted in adults with mild-to-moderate Alzheimer’s disease.

PURCHASE, N.Y., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced today that the Company’s president and CEO, Lisa Ricciardi will present at the TD Cowen 44th Annual Health Care Conference taking place March 4-6, 2024. During her presentation, Ms. Ricciardi will highlight Cognition’s pipeline progress, including upcoming clinical milestones and recent corporate achievements.

NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQCGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that collaborators at the University of Edinburgh, Scotland published findings in the journal, Acta Neuropathologica, (doi: 10.1007/s00401-023-02679-6) that provide new insight into the biology of Alzheimer’s disease that is consistent with our understanding of the role the σ-2 receptor has in regulating Aβ oligomer binding. 

Topline data from Phase 2 SHINE trial in patients with mild-to-moderate Alzheimer's disease anticipated in mid 2024

PURCHASE, N.Y., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its seventh Conversations video podcast episode: “Quantitative EEG - Effects of CT1812 on Measures of Synaptic Function in Alzheimer’s Disease.” This episode will feature a review and interactive discussion of the results from Cognition’s Phase 2 SEQUEL study, which were presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference.

NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQCGTX) is presenting in vivo preclinical results at the Society for Neuroscience’s annual meeting illuminating the role of sigma-2 (σ-2) receptor modulators, including CT1812, in models of Alzheimer's and Parkinson’s diseases.

- Top-line results expected mid 2024 -- Strong physician interest drove SHINE study completion -

Phase 2 trials in mild-to-moderate Alzheimer’s disease and dementia with Lewy bodies advancing

NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQCGTX) announced that Christoper van Dyck, M.D., the director of the Yale Alzheimer's Disease Research Unit and the Yale Alzheimer's Disease Research Center, is presenting the Phase 2 study design of the company’s ongoing START study in an oral late-breaking session at Clinical Trials on Alzheimer’s Disease (CTAD) conference. The START Study is assessing once-daily oral CT1812 or placebo in 540 individuals with early Alzheimer’s disease for 18 months of treatment. Cognition Therapeutics is conducting the study in collaboration with the Alzheimer's Clinical Trials Consortium (ACTC) with major grant support from the National Institute of Aging (NIA) at the National Institutes of Health.

PURCHASE, N.Y., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) announced that Willem de Haan, M.D., Ph.D., a neurologist and senior researcher at the Amsterdam University Medical Centers’ Alzheimer Center, is presenting complete EEG findings from the Phase 2 SEQUEL study at the Clinical Trials on Alzheimer’s Disease (CTAD) conference. SEQUEL was conducted at the Amsterdam UMC in the Netherlands with Everard (Jort) Vijverberg, M.D., Ph.D., acting as principal investigator. The poster describing changes in brain wave patterns in adults with mild-to-moderate Alzheimer’s disease following 28-days of treatment with CT1812 or placebo will be on display through the conclusion of CTAD.

Complete EEG results from SEQUEL study to be unveiled, demonstrating beneficial impact of CT1812 on brain synaptic function

PURCHASE, N.Y., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its sixth “Conversations” video podcast, which features an interactive discussion with retinal specialists about dry age-related macular degeneration (dry AMD) and the current treatment landscape. Dry AMD is caused by a degeneration of the macula and gradual loss of central vision. An estimated 1.5 million people in the United States are affected by late-stage dry AMD, which can result in permanent vision loss.

PURCHASE, N.Y., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), announced that Lisa Ricciardi, Chief Executive Officer, will deliver a company presentation at the H.C. Wainwright Annual Global Investment Conference and participating on a panel at the Cantor Fitzgerald Global Healthcare Conference in September 2023. In addition, she will be moderating a panel on pipeline prioritization strategies at the Longwood Healthcare Leaders Fall Conference, a brainstorming forum of pharmaceutical, healthcare and investment leaders focused on accelerating the translation of discoveries into medicines.

Announced Positive Topline Results from CT1812 Phase 2 SEQUEL Study in Mild-to-Moderate Alzheimer’s Disease

PURCHASE, N.Y., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), today announced that the Company will release financial results for the second quarter on Tuesday, August 8, 2023 before the market opens. Following the release, management will host a conference call at 8:00 a.m. ET on the same day to review financial results and provide a business update.

NEW YORK, July 11, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQCGTX) announced that it has dosed the first participant in the Phase 2 MAGNIFY study of CT1812, an experimental therapy being developed for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD). The MAGNIFY study (COG2201, NCT05893537) is a randomized, placebo-controlled trial that is expected to enroll approximately 246 adults, who have been diagnosed with dry AMD with measurable GA. In contrast with many development-stage dry AMD therapies that are administered by intravitreal injection, CT1812 will be given orally, once daily for 24 months to determine if it can slow disease progression as measured by changes in GA lesion size.

NEW YORK, July 05, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQCGTX) announced that the first clinical trial site has been activated and can begin recruiting participants for the 540-patient Phase 2 START study of CT1812 in adults with early Alzheimer’s disease. The University of Kentucky Sanders-Brown Center on Aging (SBCoA) is the first of approximately 50 sites in North America that has been activated by the Alzheimer's Clinical Trials Consortium (ACTC). The ACTC, founded in 2018 with funding from the National Institute on Aging (NIA), part of the National Institutes of Health, is one of the NIA’s largest public-private partnerships.

Results Show Positive Treatment Effect of CT1812 on Global and Regional Brain Activity

Call and webcast will take place at 8:00am ET

PURCHASE, N.Y., June 20, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced today that Lisa Ricciardi, president and chief executive officer will participate on a panel during Cantor Fitzgerald’s virtual Brain Week 2023 conference, which will be held June 20-23, 2023. The panel of business and scientific experts from neuroscience-focused biotechnology companies will discuss emerging targets and differentiated strategies aimed at addressing the complex mechanisms that drive Alzheimer’s disease.

PURCHASE, N.Y., June 02, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced today that the Company’s president and CEO, Lisa Ricciardi will participate in two conferences designed to introduce life science innovations to investors and other stakeholders. First, Ms. Ricciardi will participate on a panel focused on advances in neuroscience during the Longwood Healthcare Leaders Spring MIT Conference, which is taking place on June 7-8, 2023 at MIT’s Koch Institute. Second, during a panel at the Mass General Brigham World Medical Innovation Forum, which is being held June 12-14, 2023 in Boston, MA, she will be discussing advancements in the treatment of CNS diseases such as Alzheimer’s disease and dementia with Lewy bodies.

PURCHASE, N.Y., May 23, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its fifth “Conversations” video podcast, a review and interactive discussion of Cognition’s CT1812 biomarker results presented at AD/PD™ 2023, the Alzheimer's & Parkinson's Diseases Conference. Cognition VP of research, Mary Hamby, PhD presents findings from an unbiased proteomic analysis of combined datasets from the first cohort of the Phase 2 SHINE study and the completed Phase 1b SPARC study, both conducted in mild-to-moderate Alzheimer's disease patients and similarly treated with either CT1812 or placebo.

- First Human Evidence that CT1812 Selectively Engages Aβ Oligomers

Completed enrollment for Phase 2 SEQUEL trial in mild-to-moderate Alzheimer’s disease (AD); topline results expected 2Q 2023

PURCHASE, N.Y. , May 01, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), today announced the appointment of John Doyle to the role of chief financial officer. Mr. Doyle has substantial experience leading and managing financial operations at development- and commercial-stage public life sciences companies through financings, mergers, acquisitions and licensing agreements.

NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQCGTX) will be presenting in vitro results characterizing the role of sigma-2 (σ-2) receptors and effect of CT1812 in cell-based models of dry age-related macular degeneration (AMD). CT1812 is an experimental orally delivered, small molecule drug candidate that binds to σ-2 receptors, which have been shown to regulate key cellular processes involved in age-related degenerative diseases.

International Journal of Molecular Science Review Presents Mechanistic Rationale for Sigma-2 Receptor Modulation in Alzheimer’s Disease, Dementia with Lewy Bodies and Geographic Atrophy

NEW YORK, March 28, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQCGTX) presented results of a meta-analysis from the first cohort (SHINE-A) of 24 participants in the Phase 2 SHINE (COG0201; NCT03507790) and the complete dataset from the Phase 1b SPARC (COG0105; NCT03493282) studies in adults with mild-to-moderate Alzheimer's disease who were treated with either CT1812 or placebo. Treatment with CT1812 was associated with statistically significant and directionally positive effects on key proteins and corresponding Alzheimer’s disease pathways. These included:

PURCHASE, N.Y., March 27, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”) has released its fourth “Conversations” video podcast, a two-part conversation about dementia with Lewy bodies (DLB) focusing on the overlapping symptoms and pathology of DLB, Alzheimer's and Parkinson's diseases. Four neuroscience thought leaders with a wealth of experience in diagnosing and managing dementia share their insights into the nuanced symptoms and signs that help them differentiate DLB from other dementias such as Alzheimer’s disease.

- Completed enrollment of CT1812 Phase 2 SEQUEL study for mild-to-moderate Alzheimer's disease

- CEO Participating on Panel Hosted by Alzheimer’s Drug Discovery Foundation -

Conference Call and Live Audio Webcast Scheduled for Thursday, March 23, 2023, 8:00 a.m. ET

Conference Call and Live Audio Webcast Scheduled for Wednesday, March 23, 2023, 8:00 a.m. ET

NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQCGTX) announced that its Investigational New Drug (IND) application for the investigation of CT1812 for geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) has been cleared by the U.S. Food and Drug Administration (FDA). Cognition plans to initiate the Phase 2 MAGNIFY trial of its oral drug candidate, CT1812 in 2023 in individuals with dry AMD who have measurable GA.

PURCHASE, N.Y., March 07, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced today that the Company’s president and CEO, Lisa Ricciardi will present at the annual Oppenheimer & Co Healthcare Conference taking place in a virtual format from March 13-15, 2023.

NEW YORK, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQCGTX) announced that it has cleared the U.S. Food and Drug Administration comment period and may now proceed with the 540-patient Phase 2 START study of CT1812 in adults with mild cognitive impairment or early Alzheimer’s disease. This randomized placebo-controlled trial will be conducted at approximately 50-to-60 sites in North America including those premier institutions in the Alzheimer's Clinical Trials Consortium (ACTC). CT1812 is an investigational oral small molecule that binds to a receptor on synapses and is designed to prevent the toxic effects of soluble beta amyloid (Aβ) oligomers on neurons, which drive the progression of neurodegenerative diseases such as Alzheimer’s disease.

PURCHASE, N.Y., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its third “Conversations” video podcast, featuring a discussion with two Lewy body dementia caregivers, who are also passionate advocates for the second most common and devastating form of dementia. They describe their experiences and journey as caregivers through the difficult process of getting an accurate diagnosis and finding resources and support for their loved ones.   In addition, they provide valuable insights on the key symptoms that define Lewy Body dementia, preparing for doctor visits and where to turn for resources and support.

Innovative Trial Explores Theta Wave qEEG as a Biomarker of Synaptic Dysfunction

- Features Alzheimer’s Experts: Christopher van Dyck, M.D. and Anton Porsteinsson, M.D. -

PURCHASE, N.Y., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced today that the Company’s management team will participate in the 6th Annual Sachs Neuroscience Forum, Biotech Showcase and BIO Partnering @ JPM. All events will be held in-person and are scheduled alongside the J.P. Morgan 41st Annual Healthcare Conference 2023.

SHINE Study Expanded from USA to Include sites in Spain, the Netherlands, and Czech Republic

PURCHASE, N.Y., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) today announced that the scientific rationale, supporting proof-of-concept data and design of the planned Phase 2 trial of CT1812 in geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) will be communicated in an oral presentation at the 2022 Dry AMD Therapeutic Development Summit. Age-related macular degeneration is the leading cause of irreversible central vision loss in the world, with dry AMD affecting an estimated 10 million people in the U.S., 1.5 million of whom have advanced disease or GA.

Innovative trial addresses second most common dementia after Alzheimer’s disease, now enrolling patients at up to 30 activated sites across the USA

PURCHASE, N.Y., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) has introduced a new podcast/webinar series named “Conversations,” that will feature virtual fireside chats with neuroscience experts to discuss advances in the research and treatment of Alzheimer’s disease, dementia with Lewy bodies (DLB), and other age-related neurodegenerative conditions.

PURCHASE, N.Y., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) today announced the closing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $1.20 per share. The gross proceeds to Cognition, before deducting underwriting discounts and commissions and estimated offering related expenses, were approximately $6.0 million. In addition, Cognition has granted the underwriters a 30-day option to purchase an additional 750,000 shares of its common stock.